Spots Global Cancer Trial Database for antigens, cd30
Every month we try and update this database with for antigens, cd30 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | NCT01100502 | Disease, Hodgki... | brentuximab ved... placebo | 18 Years - | Seagen Inc. | |
| A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | NCT00848926 | Disease, Hodgki... | brentuximab ved... | 12 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01421667 | Lymphoma, B-Cel... Lymphoma, Large... Lymphoma, Non-H... Lymphoma, T-Cel... | brentuximab ved... rituximab | 6 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma | NCT00866047 | Lymphoma, Large... Lymphoma, Non-H... | brentuximab ved... | 12 Years - | Seagen Inc. | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | NCT01309789 | Lymphoma, Large... Lymphoma, NK-ce... Lymphoma, T-cel... | brentuximab ved... cyclophosphamid... brentuximab ved... prednisone cyclophosphamid... doxorubicin doxorubicin prednisone vincristine | 18 Years - | Seagen Inc. | |
| Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | NCT01026233 | Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... | brentuximab ved... | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma | NCT01950364 | Hodgkin Lymphom... Anaplastic Larg... | brentuximab ved... Brentuximab ved... | 18 Years - 75 Years | Millennium Pharmaceuticals, Inc. | |
| ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | NCT01777152 | Anaplastic Larg... Non-Hodgkin Lym... T-Cell Lymphoma | brentuximab ved... doxorubicin prednisone vincristine cyclophosphamid... | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - | Takeda | |
| Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma | NCT01874054 | Hodgkin Disease | brentuximab ved... bendamustine | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | NCT01309789 | Lymphoma, Large... Lymphoma, NK-ce... Lymphoma, T-cel... | brentuximab ved... cyclophosphamid... brentuximab ved... prednisone cyclophosphamid... doxorubicin doxorubicin prednisone vincristine | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | NCT01925612 | Lymphoma, B-cel... Lymphoma, Large... | brentuximab ved... brentuximab ved... rituximab vincristine cyclophosphamid... prednisone doxorubicin | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01421667 | Lymphoma, B-Cel... Lymphoma, Large... Lymphoma, Non-H... Lymphoma, T-Cel... | brentuximab ved... rituximab | 6 Years - | Seagen Inc. | |
| A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study | NCT00947856 | Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... | brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | NCT00649584 | Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... | SGN-35 gemcitabine | 12 Years - | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
